NPR News

Many signs are in the Cyrillic alphabet. The men and women sitting in the cafes are speaking Russian. The shops sell vodka, black bread, pickled herring and Russian-brewed Baltika beer. You have to pinch yourself to remember where you are.

This scene, with all its echoes of the former Soviet Union, is not in St. Petersburg or Vladivostok, or anywhere else in that vast sweep of bleak northern lands. It is in Ashdod, Israel, a palm-lined, pastel-colored port city that sprawls along the mild shores of the Mediterranean.

The drama over the fiscal cliff and the familiar up-against-a-deadline dysfunction of Congress have largely overshadowed the leave-taking of some Capitol Hill originals.

So we wanted to remember a few true congressional trailblazers whose long Washington careers are ending. They include the first openly gay member of Congress, a leader of the libertarian movement, the first Jewish candidate to run on a major party presidential ticket, and the most fervent supporter of a U.S. Department of Peace.

What a brilliant year for live music 2012 was. And I saw an awful lot of it: 462 performances, by my count. I know that sounds insane — more concerts than days in a year. Many of those were full concerts, but sometimes at music festivals I'd run from club to club or stage to stage just to catch a song or two. It's all part of a quest to find new music and hear new talent. Even a short taste helps me know whether I need to pay attention to a burgeoning band or whether a classic act seems to give a damn anymore.

The promise of genetic medicine is beginning to be fulfilled, but it's been a long, hard slog.

Take the story of Kalydeco. It's designed to treat people with a lung disease called cystic fibrosis. While not quite a cure, the drug is extremely effective for some CF patients.

But the success of Kalydeco has been more than two decades in the making.